Puma Biotechnology Inc · NASDAQ:PBYI

Puma Biotechnology — Q3 2022 Earnings Presentation

8 slides from Puma Biotechnology's earnings presentation, Nov 3, 2022

  1. Slide 1: Puma Biotechnology Earnings Call Commercial Update

    Puma Biotechnology Earnings Call Commercial Update November 3, 2022

  2. Slide 2: Forward-Looking Safe-Harbor Statement

    Forward-Looking Safe-Harbor Statement This presentation contains forward-looking statements, including statements regarding commercialization of NERLYNX® and the potential indications and development of our drug candidates. All forward-looking statements involve risks and uncertainties that could ca

  3. Slide 3: PUMA's Pharmacy and Distributor Network

    PUMA’s Pharmacy and Distributor Network Hub Services Specialty Pharmacy Network (SP) Acaria Health Accredo CVS ONCO 360 Patients Optum / Biologics Diplomat Sites of Care Specialty Distributor Network (SD) Academic Hospitals McKesson Community Hospitals ASD/Oncology Supply Physician Practices Cardina

  4. Slide 4: ~$54 Million net NERLYNX revenue in Q3'22

    ~$54 Million net NERLYNX revenue in Q3’22 Quarterly Net Revenue (in $MM) 61.1 58.7 53.8 53.5 54.3 52.6 51.3 50.8 50.0 51.0 48.6 48.8 49.3 48.9 45.6 45.8 43.4 40.7 36.0 20.1 6.1 Copyright 2022 Puma Biotechnology 4

  5. Slide 5: 3,197 Ex-factory bottles were sold in Q3'22

    3,197 Ex-factory bottles were sold in Q3’22 Bottles Sold (SP + SD) by Quarter 5,538 4,936 4,935 4,799 4,791 4,696 4,452 4,035 3,728 3,611 3,517 3,585 3,454 3,247 3,354 3,200 3,197 2,947 2,680 2,137 675 Includes Commercial SP and SD Copyright 2022 Puma Biotechnology 5

  6. Slide 6: ~68% of patients in Q3'22 started at a reduced dose

    ~68% of patients in Q3’22 started at a reduced dose* ** % of Patients starting at reduced dose 67.9% 65.4% 61.5% 59.4% 54.9% 42.4% 37.7% 38.7% 32.8% 30.0% 31.0% 28.0% 19.0% 12.0% 11.0% 6.0% 7.0% 3.0% 4.0% 2.0% 2.0% *Reduced dose defined as fewer than 6 pills per day ** FDA approved dose-escalation l

  7. Slide 7: Rest of World Partnerships – Timelines

    Rest of World Partnerships – Timelines Region Partner Regulatory Approvals Commercial Launches • 2019 – Ext. Adj. in Australia, Singapore • 2020 – Singapore • 2020 – Ext. Adj. in Brunei, Malaysia, New Zealand Australia / SE Asia • Q2 2021 – Malaysia • Q2 2022 – Ext. Adj. in the Philippines • Q3 / Q4

  8. Slide 8: Puma Biotechnology Earnings Call Commercial Update

    Puma Biotechnology Earnings Call Commercial Update November 3, 2022

Puma Biotechnology — Q3 2022 Earnings Presentation on 6ix